Research Article

Vitamin D Supplementation Ameliorates Metabolic Dysfunction in Patients with PCOS: A Systematic Review of RCTs and Insight into the Underlying Mechanism

Shan Guo,¹ Reshef Tal,² Haoyu Jiang,³ Tao Yuan,¹ and Ying Liu ¹

¹Department of Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China

²Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06510, USA

³Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Correspondence should be addressed to Ying Liu; yingliubj@hotmail.com

Received 17 June 2020; Revised 30 October 2020; Accepted 6 December 2020; Published 22 December 2020

Academic Editor: Silvia Monticone

Copyright © 2020 Shan Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Evidence suggests that vitamin D deficiency correlated with metabolic disorders in women with polycystic ovary syndrome (PCOS). We conducted this systematic review and meta-analysis to evaluate the impact of vitamin D supplementation alone on glucose, lipid, and androgen parameters and inflammation biomarkers in women with PCOS. *Methods.* Literature research was conducted in Pubmed, Embase, Web of Science, Clinical Trials, and Cochrane Library to identify relevant randomized controlled trials (RCTs) up to March 2020. The effect of vitamin D supplementation alone on women with PCOS was compared with administration of placebo. The systematic review and meta-analysis protocol was registered in the International Prospective Register of Systematic Reviews (Prospero) as number CRD42020157444. *Results.* Thirteen randomized controlled trials with 824 patients in total were included. Serum FPG, fasting insulin, HOMA-IR, and VLDL-C were significantly decreased in the vitamin D group versus placebo. Vitamin D supplementation group also showed a significantly elevated level of QUICKI. No significant impact was seen on serum triglyceride, total-C, LDL-C, HDL-C, total testosterone, DHEAS, SHBG, or hs-CRP. Subgroup analysis demonstrated that oral vitamin D intake had significantly decreased serum triglyceride and total-C level in women with PCOS who have vitamin D deficiency (serum vitamin D < 20 ng/ml). *Conclusion.* The findings of the present meta-analysis indicate that vitamin D supplementation exerted favorable effects among women with PCOS on glucose metabolism and lipid metabolism, especially in vitamin D deficient women, but had no significant effect on the androgenic profile or inflammation status.

1. Introduction

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting 6–10% of reproductive age women [1]. The main clinical manifestations of PCOS are irregular menstruation, polycystic ovarian morphology, hyperandrogenism, and infertility [2]. Women with PCOS are more prone to suffer from metabolic disorders including insulin resistance, dyslipidemia, and hypertension leading to increased long-term cardiovascular risk [3]. At present, treatments for patients with PCOS include life style interventions and drug therapy aiming at restoring menstruation and providing endometrial protection, decreasing androgen levels, and lowering insulin resistance [4]. Since the etiology and pathogenesis of the syndrome remain obscure, there is no specific therapy for this population. High prevalence of PCOS and its negative influence on both physical and psychological health of women have drawn important public health concerns.

Until now, metformin has been the first-line treatment for patients with PCOS who have insulin resistance, but associated side effects such as abdominal pain, diarrhea, or headache are common [5]. It is necessary to find a safe and economical treatment for these patients. Vitamin D is responsible for bone health by enhancing intestinal absorption of calcium [6]. Its importance in reproduction has become increasingly recognized over the past decade [7]. The receptor for vitamin D is expressed in several reproductive tissues including the ovary, uterus, and placenta [8, 9]. Recent data from human studies suggests that vitamin D deficiency may be associated with reproductive disorders including PCOS. A meta-analysis comprising fourteen studies including a total of 2,262 women (1,150 patients with PCOS/1,162 controls) reported serum 25-hydroxyvitamin D was significantly lower in patients with PCOS than controls [8].

Vitamin D deficiency is defined as a 25-hydroxyvitamin (25-OH)D serum concentration of less than 20 ng/ml, while vitamin D insufficiency occurs at a level from 20 ng/ml to <30 ng/ml [10]. Numerous randomized controlled trials (RCT) have been conducted to evaluate the potential therapeutic effect of vitamin D supplementation in women with PCOS having vitamin D deficiency or insufficiency. Several published systematic review and meta-analyses have been performed, indicating that vitamin D oral supplementation had a little overall effect on metabolic status among patients with PCOS [11-16]. However, most of those articles included either non-RCTs or cosupplemented trials (with metformin or other nutrients), which may mask the real effect of vitamin D supplementation. Moreover, those published reviews tended to focus on one specific area, which may prevent us from getting a thorough understanding of the potential beneficial effects of vitamin D supplementation. Due to the conflicting results of vitamin D supplementation effects on glucose, lipid, androgenic, and inflammatory profile, we conducted a comprehensive systematic review and meta-analysis focusing on RCTs and studies only employing vitamin D supplementation alone without cosupplementation to reach a more convincing conclusion.

2. Methods

2.1. Registration. The protocol for this systematic review was registered in the International Prospective Register of Systematic Reviews (Prospero) as number CRD42020157444 [17]. This systematic review and meta-analysis process and manuscript development complied with the PRISMA guidelines [18].

2.2. Literature Search. Pubmed, Embase, Web of Science, Cochrane Library, and Clinical Trials were searched up to March 22, 2020, with the following MeSH and non-MeSH terms: "vitamin D", "vitamin D3", "vitamin D2", "cholecalciferol", "ergocalciferols", "hydroxycholecalciferol" or "calcitriol" combined with "polycystic ovary syndrome", "ovary polycystic disease", "PCOS", "stein-Leventhal syndrome", "stein-Leventhal syndrome". The reference lists of identified literatures were also browsed to identify any potential additional publications. No restrictions were made for language or date of publications.

2.3. Inclusion and Exclusion Criteria. Inclusion criteria were as follows: (1) RCTs; (2) study subjects were women diagnosed with PCOS; (3) PCOS was diagnosed on the basis of the 2003 Rotterdam criteria or the 1990 National Institute of Child Health and Human Development criteria; (4) full text was accessible; (5) studies comparing the therapeutic effect of vitamin D supplement with placebo.

Exclusion criteria were as follows: (1) studies examining the effects of vitamin D combination with other interventions such as metformin, calcium, oral contraceptive, and so on; (2) studies examining the effects of vitamin D among patients with PCOS undergoing intrauterine insemination (IUI) or in vitro fertilization (IVF) treatment; (3) incomplete data; (4) genetic research.

2.4. Study Selection and Data Extraction. Literature searches were conducted by two reviewers (S. G. and H. Y. J.) separately, and then the title and abstract were screened for eligibility. Full texts retrieved were carefully checked according to the inclusion and exclusion criteria to select qualified trials independently. Disputes were solved through discussion with another reviewer (T. Y.), and consensus was reached.

Data extraction were carried out by two reviewers (S. G. and H. Y. J.), and the following information was extracted: the last name of the first author, publishing year, country, criteria used for diagnosis of PCOS, study population, sample size, type and duration of intervention, dose of vitamin D intake, serum vitamin D level, biochemical indices of glucose and lipid metabolism including fasting plasma glucose (FPG), fasting insulin, HOMA-IR, QUICKI, serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein cholesterol (VLDL-C), hypersensitive C-reactive protein (hs-CRP), total testosterone (Total T), sex hormonebinding globulin (SHBG), and dehydroepiandrosterone sulfate (DHEAS). Any discrepancies were resolved by discussion with another reviewer (T. Y.). In the event of incomplete information, authors were contacted to acquire relevant data.

2.5. Quality Assessment. The Cochrane risk of bias assessment tool was employed to evaluate the method of randomization, allocation of concealment, blinding of participants, personnel and outcome assessment, incomplete outcome, selective reporting, and other biases. Risk bias of each study was graded as low, unclear, and high. Any dispute was resolved by consensus.

2.6. Statistical Analysis. Statistical synthesis and subgroup analysis were performed by Revman V.5.3 offered by the Cochrane Collaboration. Measurement data were displayed as mean difference and standard deviation. Mean difference (MD) with 95% confidence intervals (CI) by inverse variance method was employed in case of data with identical measuring units; otherwise, standard mean difference (SMD) was adopted. Heterogeneity among studies was estimated by Cochran's Q test and I-squared. P < 0.10 with $I^2 > 50\%$ indicates statistical heterogeneity. When significant heterogeneity presented, the random-effects model of meta-analysis was applied. Publication bias was assessed by funnel plots.

3. Results

3.1. Literature Search. The online database search yielded 329 articles. After removing 147 duplicates, 182 articles were excluded by screening the title and abstract, and then, the remaining 61 articles were inspected carefully for eligibility. Studies without outcomes of interest (n = 3), study population (n = 3), and types of intervention (n = 32): concomitant metformin use, n = 5; concomitant OCP use, n = 1; concomitant other nutrients use, n = 26) not accordant with the inclusion criteria, studies without control group (n = 3), studies with incomplete data (n = 1), and studies without full text (n = 6) were excluded. Finally, 13 RCTs were selected according to the inclusion and exclusion criteria. The flowchart detailing selection of studies is presented in Figure 1.

3.2. Characteristics of Included RCTs. These papers were published from 2012 to 2019 and conducted in Iran [19–26], India [27], Austria [28], Venezuela [29], the United Kingdom [30], and the United States [31] A total of 824 women with PCOS aged 18–40 years were included, and the duration of intervention was 8 weeks, 12 weeks, or 24 weeks. The dose of vitamin D intake varied from 2000 IU/week to 50,000 IU/week. Essential features of trials included in the meta-analysis are summarized in Table 1. The overall risk of included trials was estimated to be low. The quality evaluation of included trials is shown in Figure 2.

3.3. Serum Vitamin D Levels. Twelve studies reported significant increase in serum vitamin D level following supplementation. The baseline serum level of 25(OH)D in intervention group ranged from 3.5 ± 4.2 ng/ml to 19.55 ± 6.73 ng/ml, indicating that selected patients with PCOS were mostly vitamin D deficient. Combination of data extracted from thirteen studies revealed a significant increase in 25(OH)D concentrations in the vitamin D treatment group versus placebo (MD: 16.19 ng/ml, 95% CI: 13.30, 19.09) (Figure 3).

3.4. Glucose Metabolism Biomarkers. Nine studies were evaluated for FPG level. Meta-analysis showed serum FPG level of patients with PCOS significantly decreased after vitamin D supplementation (SMD: -0.34, 95% CI: -0.61, -0.07) (Figure 4(a)). Heterogeneity between studies was high (P = 0.01, $I^2 = 60\%$). The form of vitamin D agent was one of the sources of heterogeneity, and the heterogeneity could be eliminated after removal of the trial adding

calcitriol (Bonakdaran et al.) [26]. The beneficial effect on FPG level became more evident taking intake manner into account (intake by week, SMD: -0.50, 95% CI: -0.83, -0.18) (Figure 4(b)) and was independent of the extent of baseline vitamin D deficiency among patients with PCOS (vitamin D < 20 ng/ml, SMD: -0.33, 95% CI: -0.68, 0.01; vitamin D < 30 ng/ml, SMD: -0.35, 95% CI: -0.88, 0.17) (Figure 4(c)) and supplementation dose (low dose, SMD: -0.27, 95% CI: -0.62,0.07; high dose, SMD: -0.49, 95% CI: -1.07, 0.08) (Figure 4(d)).

In total, ten studies have assessed insulin resistance indices in women with PCOS, among which seven studies reported concentration of fasting insulin, and ten studies reported HOMA-IR and six studies evaluated QUICKI. We found a significant decrease in serum fasting insulin level (SMD: -0.43, 95% CI: -0.67, -0.18) (Figure 5(a)) and HOMA-IR (SMD: -0.25, 95% CI: -0.47, -0.02) (Figure 5(b)). Meanwhile, a significant increase in QUICKI was also observed (SMD: 0.52, 95% CI: 0.11, 0.92) (Figure 5(c)). To further evaluate the potential influence of extent of vitamin D deficiency at baseline and intake interval on the observed effects, subgroup analyses were carried out and revealed that vitamin D supplementation was effective in ameliorating insulin resistance in women with PCOS who have baseline serum vitamin D < 20 ng/ml (fasting insulin, SMD: -0.40, 95% CI: -0.69, -0.10; Figure S1(a)) (HOMA-IR, SMD: -0.25, 95% CI: -0.47, -0.02; Figure S1(b)) (QUICKI, SMD: 0.52, 95% CI: 0.11, 0.92; Figure S1(c)). In addition, the effect was related to intake interval. Daily vitamin D oral intake was found to be efficacious in lowering HOMA-IR (SMD: -0.46, 95% CI: -0.72, -0.20; Figure S1(d)) and fasting insulin level (SMD: -0.44, 95% CI: -0.85, -0.04; Figure S1(e)). Meanwhile, weekly supplementation also resulted in a significant decrease in fasting insulin level (SMD: -0.56, 95% CI: -0.87, -0.26; Figure S1(e)) but had no effect on QUICKI (SMD: -0.53, 95% CI: -0.04, 1.11; Figure S1(f)). When supplementation dose was taken into consideration, low dose supplementation (<50,000 IU/week) improved fasting insulin level (SMD: -0.39, 95%CI: -0.68, -0.11; Figure S1(g)), QUICKI (SMD: 0.61, 95%CI: 0.18, 1.03; Figure S1(h)), and HOMA-IR (SMD: -0.33, 95%CI: -0.63, -0.02; Figure S1(i)) in patients with PCOS. The heterogeneity within studies was low in selected indices except for QUICKI (P = 0.004, $I^2 = 71.0\%$). When study population was stratified by serum vitamin D concentration, the heterogeneity became low.

3.5. Lipid Metabolism Biomarkers. A total of eight trials were included for assessing the effect of vitamin D supplementation on lipids, all of which reported serum triglyceride levels. Among these studies, seven trials reported serum concentrations of total-C and HDL-C, six trials reported results for LDL-C, and three trials examined serum level of VLDL-C. The overall effect of vitamin D supplementation significantly lowered serum VLDL-C level (MD: -3.83 mg/dl, 95% CI: -7.34, 0.32; Figure 6(c)) but did not affect serum concentration of total-C (SMD: -0.18, 95% CI: -0.44, 0.09; Figure 6(a)), LDL-C (SMD: -0.23, 95% CI: -0.60,0.14;



FIGURE 1: Flowchart of search strategy.

Figure 6(b)), HDL-C (SMD: 0.15, 95% CI: -0.03, 0.33; Figure 6(d)), or triglycerides (SMD: -0.23, 95% CI: -0.50, 0.03; Figure 6(e)). We also examined whether study population, intake interval, and supplementation dose were involved in vitamin D supplementation influence on lipid metabolic parameters. We found evidence that vitamin D supplementation reduced triglycerides (SMD: -0.40, 95% CI: -0.60, -0.21; Figure 6(f)) and total-C (SMD: -0.36, 95% CI: -0.60, -0.12; Figure 6(g)) significantly in vitamin D deficient patient group. Dosing interval was associated with the decrease of serum triglycerides (intake by day, SMD: -0.46, 95% CI: -0.81, -0.10; Figure 6(h)) but had no effect on total-C level (intake by week, SMD: 0.04, 95% CI: -0.20, 0.28; intake by day, SMD: -0.35, 95% CI: -0.88, 0.17; Figure 6(i)). Similarly, both low dose of vitamin D supplementation (<50,000 IU/week) or high dose (>50,000 IU/week) were not associated with significant changes in triglycerides (low dose, SMD: -0.21, 95% CI: -0.54, 0.12; high dose, SMD: -0.30, 95% CI: -0.79, 0.18; Figure 6(j)), total-C (low dose, SMD: -0.18, 95%CI: -0.54, 0.18; high dose, SMD:-0.15, 95% CI: -0.54, 0.24; Figure 6(k)), or LDL-C (low dose, SMD: -0.37, 95%CI: -0.80, 0.06; high dose, SMD: 0.06, 95%CI: -0.33, 0.46; Figure 6(l)) level. There was heterogeneity among studies when data on triglycerides (P = 0.02, $I^2 = 58\%$), total-C (P = 0.05, $I^2 = 53\%$), and LDL-C

 $(P = 0.005, I^2 = 70\%)$ were combined. Subgroup analysis found that heterogeneity resulted from discrepancy in vitamin D level of patients with PCOS and sample size.

3.6. Androgenic and Inflammatory Profile. Seven studies in total reported on serum androgens, of which five studies had results for total testosterone concentration, five trials had data on DHEAS, and four trials examined serum SHBG level. The results of the meta-analysis revealed that vitamin D supplementation in women with PCOS did not have significant effect on total testosterone (SMD: -0.18, 95% CI: -0.37, 0.02; Figure 7(a)), DHEAS (SMD: -0.02, 95% CI: -0.37, 0.22; Figure 7(b)), and SHBG (SMD: 0.37, 95% CI: -0.39, 1.13; Figure 7(c)). In addition, four studies evaluated effects on hs-CRP, and the results of our meta-analysis showed that vitamin D supplementation decreased serum concentration of hs-CRP significantly (SMD: -0.28, 95%CI: -0.62, 0.06; Figure 7(d)).

3.7. Publication Bias. The funnel plots for serum vitamin D concentrations indicated a risk for lack of reporting on negative effect of vitamin D supplementation. The funnel plots for the rest of the indices showed there was no significant publication bias. However, for each result, the number of studies of meta-

	TABLE 1: Summe	ary of RCTs focusing on the	effect of V	⁄itamin D supple	mentation in wo	men with polycystic	ovary syndror	ne.	
Author/year/ country	Population/age/vitamin D level	Intervention	Duration	250HD before treatment (g/ml)	25OHD after treatment (ng/ml)	Hyperandrogenism	Insulin resistance	Dyslipidemia	Inflammation
Seyyed et al., (2017) Iran [19]	36 women with PCOS, aged 20–38 years, 25OHD < 20 ng/ml	G1: 50,000 IU/week of oral vitamin D3 $(n = 19)$; G2: placebo $(n = 17)$	8 weeks	G1: 3.5 ± 4.2; G2: 9.8 ± 5.1	$28.24 \pm 6.47;$ 13.3 ± 7.1		JFPG ↔HOMA- IR, QUICKI		
Asemi et al., (2017) Iran [21]	104 overweight and obese women with PCOS, aged 18–40 years, 25OHD < 20 ng/ml	G1: 1000 mg/d calcium + vitamin D placebo $(n = 26)$; G2: 50,000 IU/week vitamin D + calcium placebo $(n = 26)$; G3: 1000 mg/d calcium+ 50,000 IU/week vitamin D (n = 26); G4: calcium placebo + vitamin D placebo + vitamin D	8 weeks	G1: 13.9 ± 2.0; G2: 11.6 ± 4.7; G3: 15.1 ± 3.6; G4: 14.0 ± 4.1	71.2±14.7; 86.8±16.1; 76.4±13.3; 73.5±23.8		↓insulin, ↓OMA-IR, ↑QUICKI ↔FPG	↓TG, VLDL-C ↔TC, LDL-C, HDL-C	8 weeks
Bonakdaran et al., (2012) Iran [26]	48 women with PCOS, aged 20–40 years, 25OHD < 20 ng/ml	G1: 1000 mg/d metformin (n = 17); G2: 0.5ug/d calcitriol (n = 15); G3: placebo $(n = 16)$	12 weeks	G1:28.2 ± 13.5; G2:11.4 ± 8.2; G3:19.9 ± 16.5;	$26.7 \pm 10.6;$ $20.1 \pm 16.2;$ 19.0 ± 15.3	↔Total testosterone, DHEAS	↔FPG, insulin, HOMA-IR		
Foroozanfard et al., (2015) Iran [22]	104 overweight women with PCOS who have vitamin D deficiency, aged 18–40 years, 25OHD < 20 ng/ml	G1: 1000 mg calcium/d plus vitamin D placebo weekly ($n = 26$); G2: 50,000 IU/week vitamin D plus calcium plus 50,000IU vitamin D weekly ($n = 26$); G3: 1000 mg/d calcium plus 50,0001U vitamin D weekly ($n = 26$); G4: calcium placebo daily plus vitamin D placebo weekly ($n = 26$)	8 weeks		G1: +0.3 ± 0.4; G2: +12.5 ± 1.1; G3: +9.2 ± 1.5; G4: +0.2 ± 0.6				↓hs-CRP
Gupta et al., (2017) India [27]	50 women with PCOS, aged 18–45 years, 25OHD < 30 ng/ml	G1: 12000 IU/week vitamin D $(n = 25)$; G2: placebo $(n = 25)$	12 weeks	G1: 18.56 ± 9.68; G2: Vacant	44.90 ± 9.04; vacant	↔-Total testosterone, DHEAS	↓FPG, insulin, HOMA-IR ↑ QUICKI	↔TG, TC, HDL-C	
Rahimi-Ardabili et al., (2013) Iran [25]	50 women with PCOS, aged 20–40 years, 25OHD < 20 ng/ml	G1: 50,000 IU/20 days of oral cholecalciferol (n = 24); G2: placebo $(n = 26)$	8 weeks	$G1:6.9 \pm 2.8;$ $G2:7.28 \pm 2.93$	$23.4 \pm 6.14;$ 8.57 ± 3.98			↓ TC +TG, LDL-C, HDL-C, VLDL-C	↓hs-CRP

5

Author/year/ country	Population/age/vitamin D level	Intervention	Duration	25OHD before treatment (g/ml)	25OHD after treatment (ng/ml)	Hyperandrogenism	Insulin resistance	Dyslipidemia	Inflammation
Javed et al. (2019) UK [30]	37 women with PCOS, aged 18–45 years, 25OHD < 20 ng/ml	G1: 3200IU/day vitamin D $(n = 18);$ G2: placebo $(n = 19)$	12 weeks	G1: $10.26 \pm 4.57;$ G2: 12.38 ± 4.45	$36.22 \pm 7.81;$ 19.07 ± 8.21	↔Total testosterone, SHBG	↔FPG, insulin, HOMA-IR	↔TG, TC, LDL-C, HDL-C	↔ hs-CRP
Irani et al., (2015) USA [31]	53 women with PCOS, aged 18–38 years, 25OHD <20 ng/ml	G1: 50,000 IU/week of oral vitamin D3 $(n = 35)$; G2: placebo $(n = 18)$	8 weeks	G1: 16.3 ± 0.9; G2: 17 ± 1.8	$43.2 \pm 2.4;$ 17.4 ± 1.9	↔Total testosterone, SHBG	↔ HOMA- IR	↓TG ↔HDL-C, LDL-C	
Maktabi et al., (2017) Iran [24]	60 women with PCOS, aged 18–40 years, 25OHD < 20 ng/ml	G1: 50,000 IU/2 weeks of oral vitamin D3 $(n = 30)$; G2: placebo $(n = 30)$	12 weeks	G1: 12.8 ± 4.5; G2: 14.5 ± 5.1	$27.5 \pm 9.8;$ 14.4 ± 5.2	↔ Total testosterone, SHBG, DHEAS	↓FPG, insulin, HOMA-IR, QUICKI	↔TG, TC, LDL-C, VLDL-C,	↓hs-CRP
Jorly Mejia- Montilla et al., (2018) Venezuela [29]	169 women with PCOS, aged 20–40 years, 25OHD < 20 ng/ml	G1: 5000 IU/day vitamin D $(n = 84)$; G2: placebo $(n = 85)$	12 weeks	G1:13.7 ± 4.2; G2:13.5 ± 4.4	$19.1 \pm 4.9;$ 13.3 ± 4.5		↓FPG, insulin, HOMA-IR	↓TG, TC, LDL-C ↔HDL-C	
Ardabili et al., (2012) Iran [20]	50 women with PCOS, aged 20–40 years, 25OHD < 20 ng/ml	G1:50,000 IU of oral vitamin D3 every 20 days (n = 24); G2: placebo $(n = 26)$	8 weeks	G1: 6.9±2.8; G2: vacant	23.4±6.1; vacant		↔FPG, insulin, HOMA-IR, QUICKI		
Jafari-Sfidvajani et al., (2017) Iran [23]	56 women with PCOS, aged 20–40 years, 25OHD < 20 ng/ml	G1: low-calorie diet+ 50,000 IU/week oral vitamin D3 ($n = 26$); G2: low-calorie diet + placebo ($n = 28$)	12 weeks	G1: 15.83 \pm 4.85; G2: 14.93 \pm 5.55	$43.38 \pm 12.61;$ 25.32 ± 10.13	↔Total testosterone, DHEAS, SHBG			
Trummer et al., (2018) Austria [28]	123 women with PCOS, aged≥18 years, 25OHD < 30 ng/ml	G1:20,000 IU of oral vitamin D3/week $(n = 81)$; G2: placebo $(n = 42)$	24 weeks	G1: 19.55 \pm 6.73; G2: 19.55 \pm 7.01	$36.14 \pm 8.05;$ 22.76 ± 11.82	↔Total testosterone	↔ FPG, Homa-ir, Quicki	↔TG, TC	
IU: international uni high-density lipopro protein; SHBG: sex h	:s; FPG: fasting plasma glucos tein cholesterol; LDL-C: low- normone-binding globulin; D	e; IR: insulin resistance; HOMA- -density lipoprotein cholesterol; 9HEAS: dehydroepiandrosterone	IR: homeosta VLDL-C: ve s sulfate.	sis model of assessr ry low-density lipc	nent-estimated ins protein cholesterc	ulin resistance; QUICKI: ıl; TC: total cholesterol; '	quantitative insu TG: triglyceride;	llin sensitivity che hs-CRP: high sei	ck index; HDL-C: nsitive C-reactive

TABLE 1: Continued.

6



FIGURE 2: Quality assessment for randomized controlled trials included on basis of Cochrane risk of bias assessment tool.

2

Study or subgroup V	itamin D Mean	supplen SD	nentat Total	ion Mean	Control SD	Total	Weight (%)	Mean difference IV, random, 95% CI		Mea IV, rai	n differe ndom, 9	ence 5% CI	
Abootorabi et al. (2017)	28.24	6	19	3.55	4.25	17	8.1	24.69 [21.32, 28.06]					
Asemi et al. (2017)	11.8	6	26	0.4	2.6	26	8.6	11.40 [8.89, 13.91]				-	
Bonakdaran et al. (2012)	8.7	14.03	3 15	-0.9	15.93	16	4.1	9.60 [-0.95, 20.15]			-		
Foroozanfard et al. (2015)	12.5	1.1	26	0.2	0.6	26	9.1	12.30 [11.82, 12.78]				•	
Gupta et al. (2017)	44.9	9.04	25	18.56	9.68	25	7.1	26.34 [21.15, 31.53]					
H. Rahimi-Ardabili et al. (2013	3) 16.43	6.5	24	0.78	2.3	26	8.5	15.65 [12.90, 18.40]				-	
Irani et al. (2015)	26.9	12.42	2 35	0.4	7.86	18	6.9	26.50 [21.01, 31.99]					
Javed et al. (2019)	25.96	6.8	18	6.69	7.12	19	7.5	19.27 [14.78, 23.76]				_	
Maktabi et al. (2017)	14.7	10.5	35	-0.1	4.3	35	7.9	14.80 [11.04, 18.56]					
Mejia-Montilla et al. (2018)	5.4	4.59	84	-0.2	4.45	85	9.0	5.60 [4.24, 6.96]					
R. Ardabili et al. (2012)	16.43	6.5	24	0.78	2.3	26	8.5	15.65 [12.90, 18.40]				-	
S. Jafari-Sfidvajani et al. (2017)	27.55	13.21	1 26	10.38	7.04	28	6.7	17.17 [11.46, 22.88]					
Trummer et al. (2018)	16.59	7.48	79	3.21	10.3	41	8.0	13.38 [9.82, 16.94]				-	
Total (95% CI)			436			388	100.0%	16.19 [13.30, 19.09]				•	
Heterogeneity: $tau^2 = 23.82$; ch	$i^2 = 224.$	81, d <i>f</i> =	12 (P	< 0.000	01); $I^2 =$	95%		-	50	25	0	25	50
Test for overall effect: $Z = 10.9$	7 (P < 0.0)	0001)							-30	-23		23	50
									Favou	rs (contro	I) F	avours (vi	tamın D)

FIGURE 3: Forest plot of vitamin D concentration in experimental and placebo groups.

Study or subgroup	Vitamin Mean	D suppleme SD	ntation Total	Mean	Control SD	Total	Weight (%)	Std. mean difference IV, random, 95% CI	Std. mean IV, randor	difference n, 95% CI
Abootorabi et al. (2017)	-7.67	7.66	19	1.71	7.5	17	8.3	-1.21 [-1.93, -0.49]		
Asemi et al. (2017)	-0.5	14.8	26	5.9	20.8	26	10.9	-0.35 [-0.90, 0.20]		_
Bonakdaran et al. (2012)	7.3	10.93	15	1	5.35	16	8.1	0.72 [-0.01, 1.45]	-	
Gupta et al. (2017)	82.36	8.03	25	88.24	9.25	25	10.5	-0.67 [-1.24, -0.10]		
Javed et al. (2019)	-0.1	0.46	18	0	0.34	19	9.3	-0.24 [-0.89, 0.40]		
Maktabi et al. (2017)	-3.1	7.3	35	0.5	6.3	35	12.2	-0.52 [-1.00, -0.05]		
Mejia-Montilla et al. (2018)	-4.7	6.24	84	-1.4	5.76	85	15.7	-0.55 [-0.85, -0.24]		
R. Ardabili et al. (2012)	-2.83	9.54	24	-2.73	11.54	26	10.8	-0.01 [-0.56, 0.55]		
Trummer et al. (2018)	-2	8	81	-1	7.55	42	14.3	-0.13 [-0.50, 0.25]		_
Total (95% CI) Heterogeneity: $tau^2 = 0.10$; Test for overall effect: $Z = 2$	$chi^2 = 19.9$.47 ($P = 0$.	94, d <i>f</i> = 8 (<i>P</i> 01)	327 = 0.01);	$I^2 = 609$	%	291	100.0	-0.34 [-0.61, -0.07]	-2 -1 0 Favours (vitamin D)) 1 2 Favours (control)
						(a)			
Studes on sub-susses	Vitamin	D suppleme	ntation		Control		Weight	Std. mean difference	Std. mean	difference
Study of subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, randor	n, 95% CI
1.3.1 intake by week										
Abootorabi et al. (2017)	-7.67	7.66	19	1.71	7.5	17	9.3	-1.21 [-1.93, -0.49]		
Asemi et al. (2017)	-0.5	14.8	26	5.9	20.8	26	12.2	-0.35 [-0.90, 0.20]		L
Gupta et al. (2017)	82.36	8.03	25	88.24	9.25	25	11.8	-0.67 [-1.24, -0.10]		
Maktabi et al. (2017)	-3.1	7.3	35	0.5	6.3	35	13.7	-0.52 [-1.00, -0.05]		

Heterogeneity: $tau^2 = 0.07$; $chi^2 = 7.95$, df = 4 (P = 0.009); $I^2 = 50\%$ Test for overall effect: Z = 3.02 (P = 0.003)

-2

8

1	3	2	intake	hv	dav

Subtotal (95% CI)

Trummer et al. (2018)

take by day 0.72 [-0.01, 1.45] -0.24 [-0.89, 0.40] -0.55 [-0.85, -0.24] Bonakdaran et al. (2012) 7.3 10.93 15 5.35 9.2 1 16 Javed et al. (2019) -0.10.46 18 0 0.34 19 10.4 84 -1.4 5.76 85 17.4 Mejia-Montilla et al. (2018) -4.7 6.24 Subtotal (95% CI) 117 120 37.0 -0.08 [-0.79, 0.63] Heterogeneity: $\tan^2 = 0.31$; $\operatorname{chi}^2 = 9.94$, $\mathrm{d}f = 2$ (P = 0.07); $I^2 = 80\%$ Test for overall effect: Z = 0.22 (P = 0.82) Total (95% CI) 265 100.0% -0.38 [-0.67, -0.09] 303 Heterogeneity: $tau^2 = 0.10$; $chi^2 = 18.23$, df = 7 (P = 0.01); $I^2 = 62\%$ Test for overall effect: Z = 2.56 (P = 0.01)-2 $^{-1}$ 0 1 Test for subgroup differences: $chi^2 = 1.13$, df = 1 (P = 0.29); $I^2 = 11.6\%$ Favours (vitamin D) Favours (control)

42

145

15.9

63.0

-0.13 [-0.50, 0.25]

-0.50 [-0.83, -0.18]

81

186

-1 7.55



FIGURE 4: Continued.

Study or subgroup	Vitamin Mean	D supplem SD	entation Total	Mean	Control SD	Total	Weight (%)	Std. mean difference IV, random, 95% CI		Std. m IV, rar	ean di 1dom,	fferend 95% C	ce CI	
1.4.1 initial vitamin D < 20 n	g/ml													
Abootorabi et al. (2017)	-7.67	7.66	19	1.71	7.5	17	8.3	-1.21 [-1.93, -0.49]						
Asemi et al (2017)	-0.5	14.8	26	59	20.8	26	10.9	-0.35 [-0.90, 0.20]		- <u>-</u>				
Bonakdaran et al. (2012)	7.3	10.93	15	1	5.35	16	8.1	0.72 [-0.01, 1.45]						
Javed et al. (2019)	-0.1	0.46	18	0	0.34	19	9.3	-0.24 [-0.89, 0.40]						
Maktabi et al. (2017)	-3.1	7.3	35	0.5	6.3	35	12.2	-0.52 [-1.00, -0.05]						
Meija-Montilla et al. (2018)	-4.7	6.24	84	-1.4	5.76	85	15.7	-0.55 [-0.85, -0.24]			_			
R. Ardabili et al. (2012)	-2.83	9.54	24	-2.73	11.54	26	10.8	-0.01 [-0.56, 0.55]		_				
Subtotal (95% CI)			221			224	75.2	-0.33 [-0.68, 0.01]		-				
Heterogeneity: $tau^2 = 0.13$;	$chi^2 = 17.2$	22. $df = 6$ (P = 0.009); $I^2 = 65$	5%									
Test for overall effect: $Z = 1$.	.88 ($P = 0$.	06)		,,										
1.4.2 initial vitamin D < 30 n	g/ml													
Gupta et al. (2017)	82.36	8.03	25	88.24	9.25	25	10.5	-0.67 [-1.24, -0.10]						
Trummer et al. (2018)	-2	8	81	-1	7.55	42	14.3	-0.13 [-0.50, 0.25]		-	_	-		
Subtotal (95% CI)			106			67	24.8	-0.35 [-0.88, -0.17]		-				
Heterogeneity: $tau^2 = 0.09$;	$chi^2 = 2.42$	2, df = 1 (P)	= 0.12;	$l^2 = 59\%$										
Test for overall effect: $Z = 1$.	.32 ($P = 0$.	19)												
Total (95% CI)			327			291	100.0	-0.34 [-0.61, -0.07]						
Heterogeneity: $tau^2 = 0.10$;	chi ² = 19.9	94, df = 8 (P = 0.01);	$I^2 = 60^{\circ}$	%			-			-		+	
Test for overall effect: $Z = 2$.	47 (P = 0.	01)							-2	-1	0		1	2
Test for subgroup difference	es: $chi^2 = 0$	0.00, df = 1	(<i>P</i> = 0.95	$I^{2} = 0$	%				Favours	(vitamin I	D)	Favor	urs (coi	ıtrol)
						(c)							
Study or subgroup	Vitamin	D supplem	entation		Control		Weight	Std. mean difference		Std. m	ean di	ifferen	ce	

Study or subgroup	Vitamin I	D supplem	entation		Control		Weight	Std. mean difference	Std. mean difference
Study of subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
1.30.1 low dose									
Bonakdaran et al. (2012)	7.3	10.93	15	1	5.35	16	8.1%	0.72 [-0.01, 1.45]	
Gupta et al. (2017)	82.36	8.03	25	88.24	9.25	25	10.5%	-0.67 [-1.24, -0.10]	
Javed et al. (2019)	-0.1	0.46	18	0	0.34	19	9.3%	-0.24 [-0.89, 0.40]	
Maktabi et al. (2017)	-3.1	7.3	35	0.5	6.3	35	12.2%	-0.52 [-1.00, -0.05]	
Mejia-Montilla et al. (2018)	-4.7	6.24	84	-1.4	5.76	85	15.7%	-0.55 [-0.85, -0.24]	
R. Ardabili et al. (2012)	-2.83	9.54	24	-2.73	11.54	26	10.8%	-0.01 [-0.56, 0.55]	
Subtotal (95% CI)			201			206	66.5%	-0.27 [-0.62, 0.07]	•
Heterogeneity: $tau^2 = 0.11$; o	$chi^2 = 13.0$	6, df = 5 (1)	P = 0.02);	$I^2 = 629$	%				
Test for overall effect: $Z = 1$.	56 (P = 0.1)	12)							
1.30.2 high dose									
Abootorabi et al. (2017)	-7.67	7.66	19	1.71	7.5	17	8.3%	-1.21 [-1.93, -0.49]	
Asemi et al. (2017)	-0.5	14.8	26	5.9	20.8	26	10.9%	-0.35 [-0.90, 0.20]	
Trummer et al. (2018)	-2	8	81	$^{-1}$	7.55	42	14.3%	-0.13 [-0.50, 0.25]	
Subtotal (95% CI)			126			85	33.5%	-0.49 [-1.07, 0.08]	
Heterogeneity: $tau^2 = 0.18$; of	chi ² = 6.87	df = 2 (P	= 0.03); 1	$!^2 = 71\%$					
Test for overall effect: $Z = 1$.	70 (P = 0.0)	09)							
Total (95% CI)			327			291	100.0%	-0.34 [-0.61, -0.07]	•
Heterogeneity: $tau^2 = 0.10$; o	chi ² = 19.9	4, $df = 8$ (1)	P = 0.01);	$I^2 = 60^{\circ}$	%				, , , ,
Test for overall effect: $Z = 2$.	47 (P = 0.0	01)							-2 -1 0 1 2
Test for subgroup difference	es: $chi^2 = 0$.42, $df = 1$	(P = 0.52)	$I^{2} = 0$	%				Favours (vitamin D) Favours (control)

FIGURE 4: (a) Forest plot of FPG level in experimental and placebo groups. (b) Forest plot of FPG level in women with PCOS supplemented by day, week, and 20 days. (c) Forest plot of FPG level in women with PCOS who have vitamin D deficiency or insufficiency. (d) Forest plot of FPG level in women with PCOS supplemented with low- or high-dose vitamin D.

(d)

analysis was less than 10, which may be too small to determine publication bias through funnel plots (Figures 8(a)-8(n).

4. Discussion

Several meta-analyses have been conducted concerning the effect of vitamin D supplementation on metabolic biomarkers of women with PCOS, suggesting variable beneficial effects, but the results remained conflicting. Moreover, the data of non-RCTs and cosupplementation trials were combined in most of these reviews. In view of the increasing number of RCTs regarding this topic, we conducted the present meta-analysis of RCTs focusing on the effect of vitamin D intake alone without

cosupplementation compared with placebo to reach more convincing conclusions. The results of our meta-analysis revealed that vitamin D oral intake alone improved insulin resistance parameters and reduced inflammation in patients with PCOS. Furthermore, subgroup analysis showed that lipid metabolism was also improved in vitamin D deficient group. No effects were found on serum androgen levels or inflammation status.

Vitamin D deficiency is very prevalent in women with PCOS. A recent cross-sectional study demonstrated that, compared with fertile controls, significantly lower vitamin D levels were present in women with PCOS (mean 25(OH)D of 64.5 nmol/l vs. 49.0 nmol/l, resp.); meanwhile, higher HOMA-

0, 1 1	Vitamin D	supplem	entation		Contr	ol	Weight	Std. mean difference	Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
Asemi et al. (2017)	-1.1	8.5	26	3.1	6.1	26	13.2	-0.56 [-1.11, -0.00]	
Bonakdaran et al. (2012)	-5.2	26.33	15	-5	12.85	16	9.3	-0.01 [-0.71, 0.69]	
Gupta et al. (2017)	5	3.25	25	10.34	20	25	13.0	-0.37 [-0.93, 0.19]	
Javed et al. (2019)	-1.9	11.41	18	1.1	5.46	19	10.5	-0.33 [-0.98, 0.32]	
Maktabi et al. (2017)	-1.4	3.6	35	2.6	7	35	15.8	-0.71 [-1.19, -0.23]	
Mejia-Montilla et al. (2018)	-2	3.54	84	0.5	3.66	85	25.0	-0.69 [-1.00, -0.38]	
R. Árdabili et al. (2012)	0.825	8.32	24	0.096	3.17	26	13.2	0.12 [-0.44, 0.67]	
Total (95% CI)			227			232	100.0	-0.43 [-0.67, -0.18]	•
Heterogeneity: $tau^2 = 0.04$; chi Test for overall effect: $Z = 3.44$	$i^2 = 9.22, df$ k (P = 0.0006)	= 6 (P = 0)	$(.16); I^2 =$	35%					-2 -1 0 1 2
									Favours (vitamin D) Favours (control)
						(a	ι)		

0, 1 1	Vitamin L) supplen	ientation		Contr	ol	Weight	Std. mean difference	Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
Abootorabi et al. (2017)	0.04	1.19	19	0.32	1.35	17	7.7	-0.22 [-0.87, 0.44]	
Asemi et al. (2017)	-0.3	2.5	26	0.8	1.9	26	9.5	-0.49 [-1.04, 0.06]	
Bonakdaran et al. (2012)	-1.5	5.9	15	-0.9	2.55	16	7.0	-0.13 [-0.84, 0.58]	
Gupta et al. (2017)	1	0.58	25	2.38	4.88	25	9.3	-0.39 [-0.95, 0.17]	
Irani et al. (2015)	-0.04	1.91	35	-0.06	1.17	18	9.2	0.01 [-0.56, 0.58]	
Javed et al. (2019)	-0.4	2.58	18	0.1	1.87	19	7.9	-0.22 [-0.86, 0.43]	
Maktabi et al. (2017)	-0.3	0.8	35	0.6	1.6	35	10.9	-0.70 [-1.19, -0.22]	
Mejia-Montilla et al. (2018)	-0.5	0.85	84	0	0.85	85	15.5	-0.59 [-0.89, -0.28]	
R. Ardabili et al. (2012)	0.53	2.2	24	-0.061	1.06	26	9.4	0.34 [-0.22, 0.90]	
Trummer et al. (2018)	0.34	1.67	81	0.16	1.66	42	13.7	0.11 [-0.27, 0.48]	
Total (95% CI)			362			309	100.0%	-0.25 [-0.47, -0.02]	•
Test for overall effect: $Z = 2.12$	2 (<i>P</i> = 0.03)					(ł)		Favours (vitamin D) Favours (control)
	Vitamin I) supplen	nentation		Contr	ol	Weight	Std. mean difference	Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
Abootorabi et al. (2017)	0.002	0.03	19	-0.015	0.03	17	14.4	0.55 [-0.11, 1.22]	
Asemi et al. (2017)	0.0004	0.02	26	-0.02	0.02	26	15.9	1.00 [0.43, 1.58]	
Gupta et al. (2017)	0.394	0.009	25	0.37	0.04	25	16.0	0.81 [0.24, 1.39]	
Maktabi et al. (2017)	0.01	0.01	35	-0.02	0.05	35	17.6	0.82 [0.33, 1.31]	
R. Ardabili et al. (2012)	0.0098	0.031	24	0.0051	0.027	26	16.4	0.16 [-0.40, 0.72]	
Trummer et al. (2018)	-0.008	0.04	81	-0.003	0.04	42	19.8	-0.12 [-0.50, 0.25]	
Total (95% CI)			210			171	100.0	0.52 [0.11, 0.92]	-
Heterogeneity: $tau^2 = 0.18$; ch	$i^2 = 17.47, d$	f = 5 (P =	0.004); I	$^{2} = 71\%$				ד (2 -1 0 1 2

(c)

FIGURE 5: (a) Forest plot of fasting insulin level in experimental and placebo groups. (b) Forest plot of HOMA-IR in experimental and placebo groups. (c) Forest plot of QUICKI in experimental and placebo groups.

IR and lipid abnormalities are associated with deficient vitamin D levels [32]. The recommended dose of vitamin D supplementation by the Endocrine Society Guidelines is 50,000 IU once weekly for eight weeks [33]. In our meta-analysis, most of the included patients with PCOS had insufficient vitamin D level (<30 ng/ml). After vitamin D supplementation, serum 25(OH)D concentrations in patients with PCOS increased significantly with a mean difference of 16.19 ng/ml (95% CI: 13.30, 19.09). The heterogeneity of this response is high ($I^2 = 95\%$, P < 0.00).

Test for overall effect: Z = 2.51 (P = 0.01)

Evidence from our meta-analysis showed that vitamin D supplementation resulted in lowering blood fasting glucose levels in addition to improving insulin resistance, as seen by a significant decrease in serum fasting insulin and HOMA-IR along with a slight increase in QUICKI. The results of our metaanalysis are in contrast with earlier ones by other researchers. Xue et al. [11] and Fang et al. [12] failed to find a positive effect of vitamin D supplementation on glucose metabolism in

women with PCOS. Additionally, in a more recent metaanalysis, vitamin D supplementation was found to affect glucose and HOMA-IR significantly only when cosupplemented with other nutrients [16]. Several reasons may be underlying these differences. First, the meta-analysis by Lagowska et al. incorporated RCT studies that included diverse means of intervention with different kinds of micronutrients in addition to vitamin D, which may explain more variable treatment effects [16]. Second, prior meta-analyses did not exclude studies in which commonly used medications to treat PCOS such as metformin and OCPs were used [12, 13, 16]. The use of such medications known to ameliorate insulin resistance in the placebo control group may diminish the observed effects of vitamin D intervention. Third, prior meta-analyses have also included a number of single-arm before-after studies [11], which could make the pooled results less robust. To further study the optimum way of oral vitamin D administration, we conducted subgroup analysis revealing that daily intake could

Favours (vitamin D)

CD						oran mean annerence	
5D	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
24	26	2.5	35.3	26	13.0	-0.02 [-0.56, 0.52]	
25.11	25	164.16	36.28	25	12.8	0.12 [-0.44, 0.67]	
30.86	24	0.18	31.27	26	12.5	-0.56 [-1.13, 0.01]	
56.67	35	-2	33.94	18	12.3	-0.29 [-0.87, 0.28]	
0.78	18	0	0.8	19	10.7	0.00 [-0.64, 0.64]	
20.24	84	-3.5	20.88	85	20.6	-0.56 [-0.86, -0.25]	
27.225	79	-7	43.14	42	18.2	0.18 [-0.20, 0.55]	
	291			241	100.0	-0.18 [-0.44, 0.09]	-
f = 12 (P =	$0.05); I^2$	= 53%				-	
							-1 -0.5 0 0.5 1 Favours (vitamin D) Favours (control)
5	24 3 25.11 5 30.86 56.67 0.78 20.24 27.225 <i>lf</i> = 12 (<i>P</i> =	$\begin{array}{c} 3D & 100ar \\ \hline 24 & 26 \\ 5 & 25.11 & 25 \\ 5 & 30.86 & 24 \\ 56.67 & 35 \\ 0.78 & 18 \\ 20.24 & 84 \\ 27.225 & 79 \\ \hline 291 \\ 1f = 12 \ (P = 0.05); \ I^2 \end{array}$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	SD Iotal Mean SD Iotal (70) 24 26 2.5 35.3 26 13.0 2 25 164.16 36.28 25 12.8 3 30.86 24 0.18 31.27 26 12.5 5 56.67 35 -2 33.94 18 12.3 0.78 18 0 0.8 19 10.7 20.24 84 -3.5 20.88 85 20.6 27.225 79 -7 43.14 42 18.2 291 241 100.0 16 = 12 (P = 0.05); I ² = 53% 16.2	SD Iotal Mean SD Iotal (%) IV, Fantoni, 95% CI 24 26 2.5 35.3 26 13.0 -0.02 [-0.56 , 0.52] 3 25.11 25 164.16 36.28 25 12.8 0.12 [-0.44 , 0.67] 3 0.86 24 0.18 31.27 26 12.5 -0.56 [-1.13 , 0.01] 56.67 35 -2 33.94 18 12.3 -0.29 [-0.87 , 0.28] 0.78 18 0 0.8 19 10.7 0.00 [-0.64 , 0.64] 20.24 84 -3.5 20.88 85 20.6 -0.56 [-0.86 , -0.25] 27.225 79 -7 43.14 42 18.2 0.18 [-0.24 , 0.09] 291 241 100.0 -0.18 [-0.44 , 0.09] -12 -12 ($P = 0.05$); $I^2 = 53\%$ -12 -12 ($P = 0.05$); $I^2 = 53\%$

						(a)			
	Vitamin D	supplem	entation		Contro	1	Weight	Std. mean difference	Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
Asemi et al. (2017)	4.1	18.8	26	-2.2	31.7	26	16.1	0.24 [-0.31, 0.78]	
H. Rahimi-Ardabili et al. (2013)	-10.2	29.9	24	1.58	33.9	26	15.8	-0.36 [-0.92, 0.20]	
Irani et al. (2015)	-6	31.86	35	-2	28.78	18	15.6	-0.13 [-0.70, 0.44]	
Javed et al. (2019)	0.1	0.7	18	-0.1	0.66	19	14.1	0.29 [-0.36, 0.94]	
Maktabi et al. (2017)	-6.3	24.1	35	3.2	26.8	35	17.6	-0.37 [-0.84, 0.10]	
Mejia-Montilla et al. (2018)	-8.7	12.84	84	1.8	13.25	85	20.9	-0.80 [-1.11, -0.49]	
Total (95% CI)			222			209	100.0	-0.23 [-0.60, 0.14]	
Heterogeneity: $tau^2 = 0.15$; chi^2	= 16.68, df =	= 5 (P = 0)	$.005); I^2$	= 70%				-	
Test for overall effect: $Z = 1.21$ (P = 0.23		,,						-1 -0.5 0 0.5 1
									Favours (vitamin D) Favours (control)

						(b)			
Study or subgroup	Vitamin D Mean	supplem SD	entation Total	Mean	Contro SD	l Total	Weight (%)	Mean Difference IV, random, 95% CI	Mean Difference IV, random, 95% CI
Asemi et al. (2017)	-2.4	13.1	26	3.8	9.1	26	25.0	-6.20 [-12.33, -0.07]	
H. Rahimi-Ardabili et al. (2013)	-5.26	12.4	24	1.26	10.8	26	23.0	-6.52 [-12.99, -0.05]	
Maktabi et al. (2017)	-0.1	9.3	35	1.4	4.7	35	52.0	-1.50 [-4.95, 1.95]	
Total (95% CI)			85			87	100.0	-3.83 [-7.34, -0.32]	•
Heterogeneity: $tau^2 = 3.07$; chi^2 Test for overall effect: $Z = 2.14$ (.	= 2.86, df = P = 0.03)	2 (P = 0.2	24); I ² =3	0%				-	-20 -10 0 10 20 Favours (vitamin D) Favours (control)

						(c)			
	Vitamin D	supplem	entation		Contro	1	Weight	Std. mean difference	Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
Asemi et al. (2017)	0.1	4.5	26	0.9	17.8	26	11.0	-0.06 [-0.60, 0.48]	
Gupta et al. (2017)	39.48	4.88	25	38.04	8.34	25	10.5	0.21 [-0.35, 0.76]	
H. Rahimi-Ardabili et al. (2013)	-2	5.31	24	-2.15	6.52	26	10.6	0.02 [-0.53, 0.58]	
Irani et al. (2015)	2	14.83	35	3	12.99	18	10.1	-0.07 [-0.64, 0.50]	
Javed et al. (2019)	-0.1	0.36	18	-0.1	0.46	19	7.8	0.00 [-0.64, 0.64]	
Maktabi et al. (2017)	-0.2	6.5	35	-1.2	5.7	35	14.8	0.16 [-0.31, 0.63]	
Mejia-Montilla et al. (2018)	0.3	6	84	-1.7	6.46	85	35.3	0.32 [0.02, 0.62]	
Total (95% CI)			247			234	100.0	0.15 [-0.03, 0.33]	•
Heterogeneity: $tau^2 = 0.00$; chi^2	= 2.79, df =	6(P = 0.8)	83); $I^2 = 0$	0%					
Test for overall effect: $Z = 1.60$ (1)	P = 0.11)								-1 -0.5 0 0.5 1
								Favours (vitamin D) Favours (control)	

						(d)			
	Vitamin D	suppleme	entation		Contro	l	Weight	Std. mean difference	Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
Asemi et al. (2017)	-12	65.7	26	19.4	45.7	26	11.3	-0.55 [-1.10, 0.01]	
Gupta et al. (2017)	95.32	20.64	25	101.04	39.65	25	11.3	-0.18 [-0.73, 0.38]	
H. Rahimi-Ardabili et al. (2013)	-26.29	62.1	24	6.31	54	26	11.1	-0.55 [-1.12, 0.01]	
Irani et al. (2015)	-21	124.67	35	-15	77.88	18	11.0	-0.05 [-0.62, 0.52]	
Javed et al. (2019)	-0.1	0.63	18	0	0.68	19	9.6	-0.15 [-0.79, 0.50]	
Maktabi et al. (2017)	-0.5	46.4	35	6.9	23.6	35	13.1	-0.20 [-0.67, 0.27]	
Mejia-Montilla et al. (2018)	-11.3	21.34	84	0.9	21.88	85	17.2	-0.56 [-0.87, -0.25]	
Trummer et al. (2018)	9	28.7	79	-4	47.1	42	15.4	0.36 [-0.02, 0.73]	
Total (95% CI)			326			276	100.0	-0.23 [-0.50, 0.03]	-
Heterogeneity: $tau^2 = 0.08$; $chi^2 =$	= 16.78, df =	= 7 (P = 0)	$.02$; I^2 =	= 58%					
Test for overall effect: $Z = 1.71$ (1)	P = 0.09								-1 -0.5 0 0.5 1
									Favours (vitamin D) Favours (control)

(e) FIGURE 6: Continued.

	Vitamin D	suppleme	entation		Control		Weight	Std. mean difference	Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
1.18.1 vitamin D < 20 ng/ml	$\begin{array}{c} -12 \\ -26.29 \\ -21 \\ -0.1 \\ -0.5 \\ -11.3 \end{array}$	65.7 62.1 124.67 0.63 46.4 21.34	26 24 35 18 35 84	19.4 6.31 -15 0 6.9 0.9	45.7 54 77.88 0.68 23.6 21.88	26 26 18 19 35 85	11.3 11.1 11.0 9.6 13.1 17.2	-0.55 [-1.10, 0.01] -0.55 [-1.12, 0.01] -0.05 [-0.62, 0.52] -0.15 [-0.79, 0.50] -0.20 [-0.67, 0.27] -0.56 [-0.87, -0.25]	
Subtotal (95% CI) Heterogeneity: $tau^2 = 0.00$; chi ² Test for overall effect: $Z = 4.10$ (= 4.33, d <i>f</i> = <i>P</i> < 0.0001)	5 (<i>P</i> = 0.5	222 (0); $I^2 = 0$)%		209	73.3	-0.40 [-0.60, -0.21]	•
$\begin{array}{l} 1.18.2 \ vitamin \ D < 30 \ ng/ml \\ \mbox{Gupta et al. (2017)} \\ \ Trummer \ et al. (2018) \\ \ Subtotal \ (95\% \ Cl) \\ \ Heterogeneity: \ tau^2 = 0.08; \ chi^2 \\ \ Test \ for \ overall \ effect: \ Z = 0.49 \ ($	95.32 9 = 2.45, df = P = 0.62)	20.64 28.7 1 (<i>P</i> = 0.1	25 79 104 2); $I^2 = 5$	101.04 -4 59%	39.65 47.1	25 42 67	11.3 15.4 26.7	-0.18 [-0.73, 0.38] 0.36 [-0.02, 0.73] 0.13 [-0.39, 0.65]	
Total (95% CI) Heterogeneity: $tau^2 = 0.08$; chi ² Test for overall effect: $Z = 1.71$ (Test for subgroup differences: cl	= 16.78, df = P = 0.09) $ni^2 = 3.56$, dj	= 7 (P = 0) f = 1 (P = 0)	326 .02); $I^2 =$ 0.06); I^2	58% = 71.9%	%	276	100.0	-0.23 [-0.50, 0.03]	-1 -0.5 0 0.5 1 Favours (vitamin D) Favours (control)

						(f)			
	Vitamin D	supplem	entation		Contro	1	Weight	Std. mean difference	Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
1.12.1 vitamin D < 20 ng/ml									
Asemi et al. (2017)	1.9	24	26	2.5	35.3	26	13.0	-0.02 [-0.56, 0.52]	
H. Rahimi-Ardabili et al. (2013)	-17.46	30.86	24	0.18	31.27	26	12.5	-0.56 [-1.13, 0.01]	
Irani et al. (2015)	-17	56.67	35	-2	33.94	18	12.3	-0.29 [-0.87, 0.28]	
Javed et al. (2019)	0	0.78	18	0	0.8	19	10.7	0.00 [-0.64, 0.64]	
Mejia-Montilla et al. (2018)	-15	20.24	84	-3.5	20.88	85	20.6	-0.56 [-0.86, -0.25]	
Subtotal (95% CI)			187			174	69.1	-0.36 [-0.60, -0.12]	-
Heterogeneity: $tau^2 = 0.01$; chi^2	= 4.76, d <i>f</i> =	4 (P = 0.	$(31); I^2 =$	16%					
Test for overall effect: $Z = 2.94$ (P = 0.003)								
1.12.1 vitamin D < 30 ng/ml									
Gupta et al. (2017)	167.88	25.11	25	164.16	36.28	25	12.8	0.12 [-0.44, 0.67]	
Trummer et al. (2018)	-1	27.225	79	-7	43.14	42	18.2	0.18 [-0.20, 0.55]	
Subtotal (95% CI)			104			67	30.9	0.16 [-0.15, 0.47]	
Heterogeneity: $tau^2 = 0.00$; chi^2	= 0.03, df =	1 (P = 0.	86); $I^2 =$	0%					
Test for overall effect: $Z = 1.00$ (P = 0.32)								
Total (95% CI)			291			241	100.0	-0.18 [-0.44, 0.99]	
Heterogeneity: $tau^2 = 0.07$; chi^2	= 12.74, df	= 6 (P = 0)	$(0.05); I^2 =$	= 53%					······································
Test for overall effect: $Z = 1.29$ (P = 0.20		,)=						-1 -0.5 0 0.5 1
Test for subgroup differences: ch	$i^2 = 6.69 d$	f = 1 (P =	0.010)	$I^2 = 85.1$	%				Favours (vitamin D) Favours (control)
rest for subgroup unterences, er		<i>j</i> – <u>r</u> (<u>r</u> –	0.010),	- 05.1	. /0				

							(g)							
0.1.1	Exp	erimenta	ıl		Control		Weight	Std. mean differenc	e	Std. 1	nean dif	ference		
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% C	Ι	IV, ra	andom, 9	95% CI		
1.19.1 intake by week														
Asemi et al. (2017)	-12	65.7	26	19.4	45.7	26	11.3	-0.55 [-1.10, 0.01]						
Gupta et al. (2017)	95.32	20.64	25	101.04	39.65	25	11.3	-0.18 [-0.73, 0.38]				-		
Irani et al. (2015)	-21	124.67	35	-15	77.88	18	11.0	-0.05 [-0.62, 0.52]		-				
Trummer et al. (2018)	9	28.7	79	-4	47.1	42	15.4	0.36 [-0.02, 0.73]			-			
Subtotal (95% CI)			165			111	49.0	-0.07 [-0.48, 0.33]			\bullet	•		
Heterogeneity: $tau^2 = 0.10$; chi^2	= 7.62, df	= 3 (P =	0.05);	$I^2 = 61\%$	Ď									
Test for overall effect: $Z = 0.35$ (P = 0.73)													
1.19.2 intake by two week														
H. Rahimi-Ardabili et al. (2013)	-26.29	62.1	24	6.31	54	26	11.1	-0.55 [-1.12, 0.01]						
Maktabi et al. (2017)	-0.5	46.4	35	6.9	23.6	35	13.1	-0.20 [-0.67, 0.27]		-				
Subtotal (95% CI)			59			61	24.2	-0.34 [-0.70, 0.02]		•				
Heterogeneity: $tau^2 = 0.00$; chi^2	= 0.89, df	= 1 (P =	0.35);	$I^2 = 0\%$										
Test for overall effect: $Z = 1.86$ (P = 0.06)													
1.19.3 intake by week														
Javed et al. (2019)	-0.1	0.63	18	0	0.68	19	9.6	-0.15 [-0.79, 0.50]						
Mejia-Montilla et al. (2018)	-11.3	21.34	84	0.9	21.88	85	17.2	-0.56 [-0.87, -0.25]		-			
Subtotal (95% CI)			102			104	26.8	-0.46 [-0.81, -0.10]	1					
Heterogeneity: $tau^2 = 0.02$; chi^2	= 1.28, df	= 1 (P =	0.26);	$I^2 = 22\%$, b									
Test for overall effect: $Z = 2.54$ (P = 0.01)													
Total (95% CI)			326			276	100.0	-0.23 [-0.50, 0.03]						
Heterogeneity: $tau^2 = 0.08$; chi^2	= 16.78, d	f = 7 (P = 1)	= 0.02)	$I^2 = 58$	%						-			
Test for overall effect: $Z = 1.71$ (P = 0.09)		. ,						-2	-1	0	1	2	
Test for subgroup differences: cl	$ni^2 = 2.04,$	df = 2 (1)	P = 0.3	6); $I^2 = 1$.9%]	Favours (e	experimen	ital)	Favours (control)	

International Journal of Endocrinology

0, 1 1	Vitamin D	supplem	entatic	n	Contro	1	Weight	Std. mean difference	Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI
1.13.1 intake by week									
Asemi et al. (2017)	1.9	24	26	2.5	35.3	26	15.0	-0.02 [-0.56, 0.52]	
Gupta et al. (2017)	167.88	25.11	25	164.16	36.28	25	14.6	0.12 [-0.44, 0.67]	
Irani et al. (2015)	-17	56.67	35	-2	33.94	18	14.2	-0.29 [-0.87, 0.28]	
Trummer et al. (2018)	-1	27.225	79	-7	43.14	42	20.6	0.18 [-0.20, 0.55]	
Subtotal (95% CI)			165			111	64.4	0.04 [-0.20, 0.28]	-
Heterogeneity: $tau^2 = 0.00$; c	hi ² = 1.95, d <i>f</i>	= 3 (P =	0.58);	$I^2 = 0\%$					
Test for overall effect: $Z = 0.3$	B2 (P = 0.75)								
1.13.2 intake by day									
Javed et al. (2019)	0	0.78	18	0	0.8	19	12.3	0.00 [-0.64, 0.64]	
Mejia-Montilla et al. (2018)	-15	20.24	84	-3.5	20.88	85	23.3	-0.56 [-0.86, -0.25]	
Subtotal (95% CI)			102			104	35.6	-0.35 [-0.88, 0.17]	
Heterogeneity: $tau^2 = 0.09$; c	hi ² = 2.33, d <i>f</i>	= 1 (P =	0.13);	$I^2 = 579$	%				-
Test for overall effect: $Z = 1.3$	32 (P = 0.19)								
Total (95% CI)			267			215	100.0	-0.12[-0.41.0.17]	
Heterogeneity: $tau^2 = 0.07$; c	$hi^2 = 11.15$, d	f = 5 (P)	= 0.05	$I^2 = 5^4$	5%				
Test for overall effect: $Z = 0.8$	P = 0.42	,) (I		,					-1 -0.5 0 0.5 1
Test for subgroup differences	$chi^2 = 1.77$	df = 1 ()	P = 0.13	8). $I^2 = I^2$	43 7%				Eavours (vitamin D) Eavours (control)
rest for subgroup unterented			0.1		10.770				



	Vitamin D	cupplem	antatic		Control		Weight	Std mean difference		Std me	an differ	rence		
Study or subgroup	Mean	suppient SD	Total	Mean	SD	Total	(%)	IV random 95% CI		IV ran	dom 95	% CI		
	wican	50	iotai	wicali	50	Iotai	(70)	1v, randoni, 5570 Ci		1 v, 1411	40111, 75	/0 01		
1.26.1 Low dose														
Gupta et al. (2017)	95.32	20.64	25	101.04	39.65	25	11.3	-0.18 [-0.73, 0.38]			-			
H. Rahimi-Ardabili et al. (201	3) -26.29	62.1	24	6.31	54	26	11.1	-0.55 [-1.12, 0.01]						
Javed et al. (2019)	-0.1	0.63	18	0	0.68	19	9.6	-0.15 [-0.79, 0.50]						
Maktabi et al. (2017)	-0.5	46.4	35	6.9	23.6	35	13.1	-0.20 [-0.67, 0.27]		-		_		
Mejia-Montilla et al. (2018)	-11.3	21.34	84	0.9	21.88	85	17.2	-0.56 [-0.87, -0.25]						
Trummer et al. (2018)	9	28.7	79	-4	47.1	42	15.4	0.36 [-0.02, 0.73]				-		
Subtotal (95% CI)			265			232	77.7	-0.21 [-0.54, 0.12]						
Heterogeneity: $tau^2 = 0.11$; ch	$i^2 = 15.16, d$	f = 5 (P = 5)	= 0.010	$); I^2 = 6$	7%									
Test for overall effect: $Z = 1.25$	5(P=0.21)													
1.26.2 High dose														
Asemi et al. (2017)	-12	65.7	26	19.4	45.7	26	11.3	-0.55 [-1.10, 0.01]			-			
Irani et al. (2015)	-21	124.67	35	-15	77.88	18	11.0	-0.05 [-0.62, 0.52]		-	-			
Subtotal (95% CI)			61			44	22.3	-0.30 [-0.79, 0.18]						
Heterogeneity: $tau^2 = 0.04$; ch	$i^2 = 1.48$, df	= 1 (P =	0.02):	$I^2 = 339$	6									
Test for overall effect: $Z = 1.23$	B (P = 0.22)	- (-	,,											
Total (95% CI)			326			276	100.0	-0.23 [-0.50, 0.03]						
Heterogeneity: $tau^2 = 0.08$; ch	i ² = 16.78, d	f = 7 (P = 7)	= 0.02)	; $I^2 = 58$	%									
Test for overall effect: $Z = 1.71$	(P = 0.09)								-2	-1	0	1		2
Test for subgroup differences:	$chi^2 = 0.10$	df = 1 (1	P = 0.7	5): $I^2 = 0$	7%				Earro	ura (vitami	n D)	Eavoure	(control	n.
rest for subgroup unterences.	····· ····,	(1	- 0.7		570				ravo	uis (vitaini	п <i>D</i>)	ravours	(control	J

							(j)							
	Vitamin D	supplem	entatio	n	Contro	1	Weight	Std. mean difference	S	td. mean dif	ference			_
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	I	V, random,	95% CI			
1.27.1 Low dose												-		
Gupta et al. (2017)	167.88	25.11	25	164.16	36.28	25	12.8	0.12 [-0.44, 0.67]						
H. Rahimi-Ardabili et al. (20	13) -17.46	30.86	24	0.18	31.27	26	12.5	-0.56 [-1.13, 0.01]			-			
Javed et al. (2019)	0	0.78	18	0	0.8	19	10.7	0.00 [-0.64, 0.64]			<u>↓</u>			
Mejia-Montilla et al. (2018)	-15	20.24	84	-3.5	20.88	85	20.6	-0.56 [-0.86, -0.25]						
Trummer et al. (2018)	-1	27.225	79	-7	43.14	42	18.2	0.18 [-0.20, 0.55]		_				
Subtotal (95% CI)			230			197	74.6	-0.18 [-0.54, 0.18]						
Heterogeneity: $tau^2 = 0.11$; ch	$hi^2 = 12.16, d$	f = 4 (P)	= 0.02	; $I^2 = 62$	7%									
Test for overall effect: $Z = 0.9$	6 (P = 0.34)	, .												
1.27.2 High dose														
Asemi et al. (2017)	1.9	24	26	2.5	35.3	26	13.0	-0.02 [-0.56, 0.52]						
Irani et al. (2015)	-17	56.67	35	-2	33.94	18	12.3	-0.29 [-0.87, 0.28]			-			
Subtotal (95% CI)			61			44	25.4	-0.15 [-0.54, 0.24]						
Heterogeneity: $tau^2 = 0.00$; cl	ni ² = 0.47, d <i>f</i>	= 1 (P =	0.50);	$I^2 = 0\%$										
Test for overall effect: $Z = 0.7$	5 (P = 0.46)													
Total (95% CI)			291			241	100.0	-0.18 [-0.44, 0.09]		•				
Heterogeneity: $tau^2 = 0.07$; ch	$hi^2 = 12.74, d$	f = 6 (P)	= 0.05	; $I^2 = 53$	3%						-			
Test for overall effect: $Z = 1.2$	9(P = 0.20)	, .							-2	-1	0 1	1	2	
Test for subgroup differences	$chi^2 = 0.01$	df = 1 ()	P = 0.9	2): $I^2 =$	0%				Favours (vitamin D)	Favo	ure (c	ontrol)	
and a sub-	0.01,		0.2	-,,-					1 4,0413 ((mannin D)	1 410		.011(101)	

(k)

FIGURE 6: Continued.

	Vitamin D	supplem	entatio	n	Control	l	Weight	Std. mean difference		Std. mea	n diffe	rence	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI		IV, rando	om, 95	% CI	
1.28.1 Low dose													
H. Rahimi-Ardabili et al. (201	3) -10.2	29.9	24	1.58	33.9	26	15.8	-0.36 [-0.92, 0.20]			•		
Javed et al. (2019)	0.1	0.7	18	-0.1	0.66	19	14.1	0.29 [-0.36, 0.94]			-		
Maktabi et al. (2017)	-6.3	24.1	35	3.2	26.8	35	17.6	-0.37 [-0.84, 0.10]			-		
Mejia-Montilla et al. (2018)	-8.7	12.84	84	1.8	13.25	85	20.9	-0.80 [-1.11, -0.49]					
Subtotal (95% CI)			161			165	68.3	-0.37 [-0.80, 0.06]					
Heterogeneity: $tau^2 = 0.13$; chi	$^{2} = 9.74$, dr	f = 3 (P =	0.02);	$I^2 = 699$	%								
Test for overall effect: $Z = 1.67$	(P = 0.10)												
1.28.2 High dose													
Asemi et al. (2017)	4.1	18.8	26	-2.2	31.7	26	16.1	0.24 [-0.31, 0.78]			-		
Irani et al. (2015)	-6	31.86	35	-2	28.78	18	15.6	-0.13 [-0.70, 0.44]		_	-	_	
Subtotal (95% CI)			61			44	31.7	-0.06 [-0.33, 0.46]			\bullet		
Heterogeneity: $tau^2 = 0.00$; chi	$^{2} = 0.83$, dr	f = 1 (P =	0.36):	$I^2 = 0\%$									
Test for overall effect: $Z = 0.31$	(P = 0.75)	- (-											
Total (95% CI)			222			209	100.0	-0.23 [-0.60, 0.14]		-			
Heterogeneity: $tau^2 = 0.15$; chi	$^{2} = 16.68, o$	df = 5 (P)	= 0.05)	$I^2 = 70$)%						-		
Test for overall effect: $Z = 1.21$	(P = 0.23)	· ·	,						-2	-1	0	1	2
Test for subgroup differences:	$chi^2 = 2.08$, df = 1 (1)	P = 0.13	5); $I^2 =$	52.0%				Favours (vitamin	D)	Favour	s (control)
							(l)						

FIGURE 6: (a) Forest plot of total-C level in experimental and placebo groups. (b) Forest plot of LDL-C level in experimental and placebo groups. (c) Forest plot of VLDL-C level in experimental and placebo groups. (d) Forest plot of HDL-C level in experimental and placebo groups. (e) Forest plot of triglycerides in experimental and placebo groups. (f) Forest Plot of triglycerides in women with PCOS who have vitamin D deficiency or insufficiency. (g) Forest plot of total-C in women with PCOS who have vitamin D deficiency or insufficiency. (h) Forest plot of triglycerides in women PCOS supplemented by day, week, two weeks, and 20 days. (i) Forest plot of total-C in women with PCOS supplemented by day, week, and 20 days. (j) Forest plot of triglycerides in women with PCOS supplemented with a low or high dose. (k) Forest plot of total-C in women with a low dose or high dose. (l) Forest plot of LDL-C in women with PCOS supplemented with a low dose or high dose.

o. 1 1	Vitamin	D supplement	ntation	(Control		Weight	Std. mean difference		Std. me	ean di	fference	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI		IV, ran	dom,	95% CI	
Bonakdaran et al. (2012)	12.1	43.35	15	34.5	57.4	16	7.7	-0.43 [-1.14, 0.29]				-	
Gupta et al. (2017)	0.96	0.24	25	1.65	2.4	25	12.4	-0.40 [-0.96, 0.16]					
Irani et al. (2015)	8	22.47	35	4.3	15.85	18	12.0	0.18 [-0.39, 0.75]		-			
Javed et al. (2019)	0	0.63	18	0.1	0.3	19	9.3	-0.20 [-0.85, 0.45]			•	_	
Maktabi et al. (2017)	-0.04	0.5	35	0.1	0.5	35	17.6	-0.28 [-0.75, 0.19]			-		
S. Jafari-Sfidvajani et al. (2017)	-0.15	0.4	26	-0.08	0.3	28	13.6	-0.20 [-0.73, 0.34]				-	
Trummer et al. (2018)	-0.05	0.717	78	0	0.5	41	27.3	-0.08 [-0.45, 0.30]		-		-	
Total (95% CI)			232			182	100.0	-0.18 [-0.37, 0.02]					
Heterogeneity: tau ² = 0.00; chi ² =	= 3.02, df =	6 (P = 0.81);	$I^2 = 0\%$					-					
Test for overall effect: $Z = 1.74$ (F	P = 0.08)								-2	-1	0	1	2
									Favours (vitamin D)	Favours (control)
						(a)							
	Vitamin	D supplement	ntation	(Control		Weight	Std. mean difference		Std. me	ean di	fference	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI		IV, ran	dom,	95% CI	
Bonakdaran et al. (2012)	-47	1 228 79	15	167 1	596 45	16	12.3	-0.12 [-0.82, 0.59]					

Bonakdaran et al. (2012)	-4.7	1,228.79	15	167	1,596.45	16	12.3	-0.12 [-0.82, 0.59]			1			
Gupta et al. (2017)	1.36	0.39	25	1.28	0.82	25	19.8	0.12 [-0.43, 0.68]			+•			
Irani et al. (2015)	4	87.15	35	3	80.94	18	18.9	0.01 [-0.56, 0.58]			-			
Maktabi et al. (2017)	-0.5	0.8	35	-0.5	0.9	35	27.8	0.00 [-0.47, 0.47]			+-			
S. Jafari-Sfidvajani et al. (2017)	0.13	1.58	26	0.35	1.06	28	21.3	-0.16 [-0.70, 0.37]		-	+			
Total (95% CI)			136			122	100.0	-0.02 [-0.27, 0.22]		-	\bullet	•		
Heterogeneity: $tau^2 = 0.00$; $chi^2 = 0.00$	0.62, d <i>f</i> =	4 (P = 0.96);	$I^2 = 0\%$								1			
Test for overall effect: $Z = 0.18$ (P =	= 0.86)								-1	-0.5	0	0.5	1	
									Favours (vi	tamin D)		Favours	(control)



	Vitamin	D supplemen	tation	(Control		Weight	Std. mean difference	Std.	mean o	difference	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV,	randon	n, 95% CI	
Irani et al. (2015)	1	19.56	35	4	34.55	18	25.1	-0.12 [-0.68, 0.45]				
Javed et al. (2019)	0.5	16.83	18	1	13.75	19	24.1	-0.03 [-0.68, 0.61]		-+		
Maktabi et al. (2017)	5.5	12.2	35	4	40.6	35	26.3	0.05 [-0.42, 0.52]				
S. Jafari-Sfidvajani et al. (2017)	27.55	13.21	26	10.38	7.04	28	24.5	1.62 [1.00, 2.24]				
Total (95% CI)			114			100	100.0	0.37 [-0.39, 1.13]				
Heterogeneity: $tau^2 = 0.52$; $chi^2 = 0.52$;	21.43, df =	3 (P < 0.0001); $I^2 = 8$	36%				-			-	
Test for overall effect: $Z = 0.96$ (P	= 0.34)								-2 -1	0	1	2
									Favours (vitamin	. D)	Favours	(control)
						(c)						
	Vitamin	D supplemen	tation	(Control		Weight	Std. mean difference	Std.	mean	difference	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV,	randon	n, 95% CI	
Foroozanfard et al. (2015)	-238.2	2,556	26	527.4	2,540	26	25.3	-0.30 [-0.84, 0.25]			-	
H. Rahimi-Ardabili et al. (2013)	0.17	1.9	24	0	0.81	26	24.8	0.12 [-0.44, 0.67]			—	
Javed et al. (2019)	-0.3	5.36	18	0.7	6.16	19	20.1	-0.17 [-0.82, 0.48]			_	
Maktabi et al. (2017)	-0.7	1.4	35	0.5	2.1	35	29.7	-0.66 [-1.15, -0.18]	-			
Total (95% CI)			103			106	100.0	-0.28 [-0.62, 0.06]				
Heterogeneity: $tau^2 = 0.04$; $chi^2 = 0.04$	4.52, df = 3	$P = 0.21; I^2$	$^{2} = 34\%$					-				
Test for overall effect: $Z = 1.61$ (P	= 0.11)								-2 -	1 0	1	2
									Favours (vitamin	D)	Favours	(control)
						(d)						

FIGURE 7: (a) Forest plot of total testosterone level in experimental and placebo groups. (b) Forest plot of DHEAS level in experimental and placebo groups. (c) Forest plot of SHBG level in experimental and placebo groups. (d) Forest plot of hs-CRP level in experimental and placebo groups.

reduce serum glucose and insulin level, while low-dose intake could alleviate insulin resistance conditions. The potential mechanism of the effect of vitamin D on glucose metabolism may be the result of both genomic and nongenomic effects. Increased25(OH)D enhances VDR signaling helping pancreatic β -cells restore function through BRD7/PBAF pathway [34]. The 1,25(OH)2D-VDR complex binds to the vitamin D response element of the insulin receptor in tissue improving insulin responsiveness for glucose transport and suppressing the release of proinflammatory cytokines, which are believed to mediate IR [34]. Moreover, its influence on the extracellular and intracellular calcium regulation is vital for the modulation of glucose transport in target tissues [35].

Notably, decline in serum triglycerides, total-C, and VLDL-C concentration were significant among patients with PCOS who are deficient in vitamin D in our meta-analysis. This finding is in accordance with the significant improvement of serum triglycerides level observed in the meta-analysis by Xue et al. [11]. However, in Xue's article, this effect was observed with low dose vitamin D supplementation (<50,000 IU/week) rather than high dose. However, in our study, subgroup analysis showed that a low dose of vitamin D supplementation had no impact on triglycerides or total-C level, which means that highdose vitamin D intake may be more beneficial for lipid metabolism. A clarified mechanism that can explain the beneficial effects of vitamin D on lipid metabolism is that increased intracellular calcium in the liver leads to the stimulation of microsomal triglyceride transfer protein, which participates in the formation and secretion of VLDL, resulting in decreased circulating levels of serum total-C [25]. Additionally, in a randomized controlled trial, it was shown that serum VEGF levels and TGF- β 1 to soluble endoglin (sENG) ratio is significantly decreased by vitamin D supplementation in women with

PCOS [31, 36]. The decrease in VEGF and TGF- β 1 : sENG ratio correlated with the decrease in triglycerides in the PCOS group. Increased circulating TGF- β 1 levels have been associated with various cardiometabolic conditions including obesity [37], diabetes [38], and coronary artery disease [39]. It has been suggested that higher levels of insulin, LH, and androgens increase the concentration of VEGF, leading to abnormally increased vascularity in the ovary, which may exacerbate anovulation and subfertility. TGF- β 1 upregulates the secretion of VEGF, and the resulting angiogenic imbalance may play a role in the development of metabolic syndrome and cardiovascular disease in women with PCOS [40].

In this meta-analysis, we did not find any improvement in serum total testosterone, DHEAS, or SHBG level. Similar findings were reported in the meta-analysis by Azadi-Yazdi et al. [14]. In their study, significant decrease in serum testosterone concentration was only found in single-arm before- after studies, but not in high-quality RCTs. Meanwhile, in the current meta-analysis, we found that serum hs-CRP level did not change significantly after vitamin D supplementation. Previously, a meta-analysis conducted by Akbari et al. [15] reported that vitamin D supplementation resulted in an improvement in hs-CRP of women with PCOS, but in this article, the significant decrease was evident after including three trials examining the anti-inflammatory effect of vitamin D and other nutrition. Our meta-analysis demonstrated that vitamin D supplementation alone did not influence hs-CRP level among women with PCOS.

Our meta-analysis has several strengths. It includes comprehensive research of RCTs and strict inclusion of high-quality studies, in which vitamin D intervention was given alone. This allowed for a more focused analysis of vitamin D effects in PCOS. Our work also has some



FIGURE 8: Funnel plot of standard error by standard differences in the means of plasma: (a) vitamin D; (b) FPG; (c) fasting insulin; (d) HOMA-IR; (e) QUICKI; (f) triglycerides; (g) total-C; (h) HDL-C; (i) LDL-C; (j) VLDL-C; (k) total testosterone; (l) DHEAS; (m) SHBG; (n) hs-CRP in selected trials.

limitations. There is considerable heterogeneity between studies with variable race/ethnicity and age. In addition, baseline vitamin D status, vitamin D dose, and formulation and duration of treatment of vitamin D vary between studies and are an additional source of confounding. Moreover, most of the trials included were conducted in Iran, where women are covered by clothes resulting in less exposure to sunlight, so whether the benefits of vitamin D supplementation can be generalizable to women with PCOS from all over the world is still an open question. In addition, considering the limited number of high-quality RCTs and small sample size, the conclusions of the present metaanalysis should be extrapolated with caution. However, as an inexpensive and safe treatment option, vitamin D supplementation can be implemented in women with PCOS who



FIGURE 9: Potential mechanism of therapeutic effect of vitamin D on women with PCOS.

have vitamin D deficiency. Our study may shed light on the potential mechanisms behind those discovered benefits that vitamin D deficiency may be a codeterminant factor in metabolism disorder. Taken together, vitamin D supplementation appears to influence several aspects of clinical features present in women with PCOS (Figure 9).

5. Conclusion

Our systematic review showed that oral intake of vitamin D supplementation attenuated insulin resistance and hyperlipemia, but not androgenic profile or inflammatory markers in women with PCOS who have vitamin D deficiency. Several potential mechanisms may be underlying these beneficial effects of vitamin D on clinical features of PCOS, and further research is needed to explore the complex role of vitamin D in different pathways of this metabolic disorder.

Data Availability

The data used in the study are available upon request to the corresponding author.

Conflicts of Interest

The authors report no conflicts of interest related to this work.

Acknowledgments

The authors acknowledge the instruction of statistical methods by Yang Wang. This work was supported by the National Natural Science Foundation of China (81471520), Beijing Natural Science Foundation Project (7182054), and Beijing Nova Programme Interdisciplinary Cooperation Project (Z191100001119015).

Supplementary Materials

Supplementary Figure S1: (a) forest plot of fasting insulin level in women with PCOS who have vitamin D deficiency or insufficiency; (b) forest plot of HOMA-IR in women with PCOS who have vitamin D deficiency or insufficiency; (c) forest plot of QUICKI in women with PCOS who have vitamin D deficiency or insufficiency; (d) forest plot of HOMA-IR in women with PCOS supplemented by day, week, two weeks, and 20 days; (e) forest plot of fasting insulin in women with PCOS supplemented by day, week, two weeks, and 20 days; (f) forest plot of QUICKI in women with PCOS supplemented by week, two weeks, and 20 days; (g) forest plot of fasting insulin level in women with PCOS supplemented with low- or high-dose vitamin D; (h) forest Plot of QUICKI in women with PCOS supplemented with low- or high-dose vitamin D; (i) forest plot of HOMA-IR in women with PCOS supplemented with low- or high-dose vitamin D. (Supplementary Materials)

References

- R. Pasquali and A. Gambineri, "A comprehensive approach in diagnosing the polycystic ovary syndrome," *Women's Health*, vol. 11, no. 4, pp. 501–512, 2015.
- [2] A. Dunaif, "Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis*," *Endocrine Reviews*, vol. 18, no. 6, pp. 774–800, 1997.
- [3] C. J. Alexander, E. P. Tangchitnob, and N. E. Lepor, "Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women," *Reviews in Obstetrics & Gynecology*, vol. 2, no. 4, pp. 232–239, 2009.
- [4] C. C. Douglas, B. A. Gower, B. E. Darnell, F. Ovalle, R. A. Oster, and R. Azziz, "Role of diet in the treatment of polycystic ovary syndrome," *Fertility and Sterility*, vol. 85, no. 3, pp. 679–688, 2006.
- [5] J. M. Dodd, R. M. Grivell, A. R. Deussen, and W. M. Hague, "Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes," *Cochrane Database Syst Rev*, vol. 7, p. D10564, 2018.
- [6] E. Loughrill, D. Wray, T. Christides, and N. Zand, "Calcium to phosphorus ratio, essential elements and vitamin D content of infant foods in the UK: possible implications for bone health," *Maternal & Child Nutrition*, vol. 13, 2017.
- [7] M. Irani and Z. Merhi, "Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review," *Fertility and Sterility*, vol. 102, no. 2, pp. 460–468, 2014.
- [8] J. Luk, S. Torrealday, G. Neal Perry, and L. Pal, "Relevance of vitamin D in reproduction," *Human Reproduction*, vol. 27, no. 10, pp. 3015–3027, 2012.
- [9] E. Lerchbaum and B. Obermayer-Pietsch, "Mechanisms in endocrinology: vitamin D and fertility: a systematic review," *European Journal of Endocrinology*, vol. 166, no. 5, pp. 765– 778, 2012.
- [10] K. Y. Z. Forrest and W. L. Stuhldreher, "Prevalence and correlates of vitamin D deficiency in US adults," *Nutrition Research*, vol. 31, no. 1, pp. 48–54, 2011.
- [11] Y. Xue, P. Xu, K. Xue et al., "Effect of vitamin D on biochemical parameters in polycystic ovary syndrome women: a meta-analysis," *Archives of Gynecology and Obstetrics*, vol. 295, no. 2, pp. 487–496, 2017.
- [12] F. Fang, K. Ni, Y. Cai, J. Shang, X. Zhang, and C. Xiong, "Effect of vitamin D supplementation on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials," *Complementary Therapies in Clinical Practice*, vol. 26, pp. 53–60, 2017.
- [13] V. Pergialiotis, N. Karampetsou, P. Panagopoulos, E. Trakakis, and N. Papantoniou, "The effect of Vitamin D supplementation on hormonal and glycaemic profile of patients with PCOS: a meta-analysis of randomised trials," *International Journal of Clinical Practice*, vol. 71, 2017.
- [14] M. Azadi-Yazdi, A. Nadjarzadeh, H. Khosravi-Boroujeni, and A. Salehi-Abargouei, "The effect of Vitamin D supplementation on the androgenic profile in patients with polycystic ovary syndrome: a systematic review and meta-analysis of clinical trials," *Hormone and Metabolic Research*, vol. 49, no. 03, pp. 174–179, 2017.
- [15] M. Akbari, V. Ostadmohammadi, K. Lankarani et al., "The effects of vitamin D supplementation on biomarkers of inflammation and oxidative stress among women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials," *Hormone and Metabolic Research*, vol. 50, no. 4, pp. 271–279, 2018.

- [16] K. Lagowska, J. Bajerska, and M. Jamka, "The role of vitamin D oral supplementation in insulin resistance in women with polycystic ovary syndrome: a systematic review and metaanalysis of randomized controlled trials," *Nutrients*, vol. 10, 2018.
- [17] G. Shan, "Vitamin D treatment and PCOS: a systematic review of RCTs and insight into the underlying mechanism," 2020, http://www.crd.york.ac.uk/PROSPERO/display_record. php?ID=CRD42020157444.
- [18] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement," *Annals of Internal Medicine*, vol. 151, no. 4, pp. 264–269, 2009.
- [19] A. M. Seyyed, P. Ayremlou, T. Behroozi-Lak, and S. Nourisaeidlou, "The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: a randomized placebo-controlled trial," *Gynecological Endocrinology*, vol. 34, pp. 489–494, 2018.
- [20] H. R. Ardabili, B. P. Gargari, and L. Farzadi, "Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency," *Nutrition Research*, vol. 32, no. 3, pp. 195–201, 2012.
- [21] Z. Asemi, F. Foroozanfard, T. Hashemi, F. Bahmani, M. Jamilian, and A. Esmaillzadeh, "Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome," *Clinical Nutrition*, vol. 34, no. 4, pp. 586–592, 2015.
- [22] F. Foroozanfard, M. Jamilian, F. Bahmani et al., "Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial," *Clinical Endocrinology*, vol. 83, no. 6, pp. 888–894, 2015.
- [23] S. Jafari-Sfidvajani, R. Ahangari, M. Hozoori, H. Mozaffari-Khosravi, H. Fallahzadeh, and A. Nadjarzadeh, "The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial," *Journal of Endocrinological Investigation*, vol. 41, no. 5, pp. 597–607, 2018.
- [24] M. Maktabi, M. Chamani, and Z. Asemi, "The effects of vitamin d supplementation on metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial," *Hormone and Metabolic Research*, vol. 49, no. 07, pp. 493–498, 2017.
- [25] H. Rahimi-Ardabili, G. B. Pourghassem, and L. Farzadi, "Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency," *Journal of Endocrinological Investigation*, vol. 36, pp. 28–32, 2013.
- [26] S. Bonakdaran, Z. Mazloom Khorasani, B. Davachi, and J. Mazloom Khorasani, "The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo- controlled clinical trial," *Iranian Journal of Reproductive Medicine*, vol. 10, no. 5, pp. 465–472, 2012.
- [27] T. Gupta, M. Rawat, N. Gupta, and S. Arora, "Study of effect of Vitamin D supplementation on the clinical, hormonal and metabolic profile of the PCOS women," *The Journal of Obstetrics and Gynecology of India*, vol. 67, no. 5, pp. 349–355, 2017.

- [28] C. Trummer, V. Schwetz, M. Kollmann et al., "Effects of vitamin D supplementation on metabolic and endocrine parameters in PCOS: a randomized-controlled trial," *European Journal of Nutrition*, vol. 58, no. 5, pp. 2019–2028, 2019.
- [29] J. Mejia-Montilla, E. Reyna-Villasmil, M. Andrade-Albán, M. Lozada-Meza, M. Rodríguez-Cevallos, and A. Solís-Manzano, "Suplementación de vitamina D y perfil lipídico en mujeres con síndrome de ovarios poliquísticos y deficiencia de vitamina D," *Medicina Reproductiva Y Embriología Clínica*, vol. 5, no. 3, pp. 123–131, 2018.
- [30] Z. Javed, M. Papageorgiou, H. Deshmukh et al., "A randomized, controlled trial of vitamin d supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome," *Nutrients*, vol. 11, no. 1, p. 188, 2019.
- [31] M. Irani, D. B. Seifer, R. V. Grazi et al., "Vitamin D supplementation decreases TGF-β1 bioavailability in PCOS: a randomized placebo-controlled trial," *The Journal of Clinical Endocrinology & Metabolism*, vol. 100, no. 11, pp. 4307–4314, 2015.
- [32] Y. Krul-Poel, P. P. Koenders, R. P. Steegers-Theunissen et al., "Vitamin D and metabolic disturbances in polycystic ovary syndrome (PCOS): a cross-sectional study," *PLoS One*, vol. 13, Article ID e204748, 2018.
- [33] M. F. Holick, N. C. Binkley, H. A. Bischoff-Ferrari et al., "Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline," *The Journal of Clinical Endocrinology & Metabolism*, vol. 96, no. 7, pp. 1911–1930, 2011.
- [34] Z. Wei, E. Yoshihara, N. He et al., "Vitamin D switches BAF complexes to protect β Cells," *Cell*, vol. 173, no. 5, pp. 1135–1149, 2018.
- [35] L. Kjalarsdottir, S. A. Tersey, M. Vishwanath et al., "1,25-Dihydroxyvitamin D3 enhances glucose-stimulated insulin secretion in mouse and human islets: a role for transcriptional regulation of voltage-gated calcium channels by the vitamin D receptor," *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 185, pp. 17–26, 2019.
- [36] M. Irani, D. B. Seifer, R. V. Grazi, S. Irani, Z. Rosenwaks, and R. Tal, "Vitamin D decreases serum VEGF correlating with clinical improvement in Vitamin D-deficient women with PCOS: a randomized placebo-controlled trial," *Nutrients*, vol. 9, 2017.
- [37] M. Romano, M. T. Guagnano, G. Pacini et al., "Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women," *The Journal* of Clinical Endocrinology & Metabolism, vol. 88, no. 11, pp. 5321–5326, 2003.
- [38] A. Pfeiffer, K. Middelberg-Bisping, C. Drewes, and H. Schatz, "Elevated plasma levels of transforming growth factor- 1 in NIDDM," *Diabetes Care*, vol. 19, no. 10, pp. 1113–1117, 1996.
- [39] X. Wang, S. X. Liu, and D. E. Wilcken, "Circulating transforming growth factor β 1 and coronary artery disease," *Cardiovascular Research*, vol. 34, no. 2, pp. 404–410, 1997.
- [40] R. Tal, D. B. Seifer, and A. Arici, "The emerging role of angiogenic factor dysregulation in the pathogenesis of polycystic ovarian syndrome," *Seminars in Reproductive Medicine*, vol. 33, no. 3, pp. 195–207, 2015.